CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Summit Therapeutics Inc. (SMMT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Summit Therapeutics Inc. (SMMT)

Pharmaceutical Preparations · market cap $13.1B · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Summit Therapeutics (SMMT) is a 159-employee pharmaceutical company with a ~$11.6B market cap. Its lead asset is Ivonescimab Injection, in Phase 3 for non-small cell lung cancer, and our calendar shows a PDUFA date of 2026-11-14, about 18 days after this note. Ridinilazole (Phase 3, C. difficile infection) is the other pipeline asset in our data. A partnership event was logged as completed on 2026-09-28.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
RidinilazolePhase 3Clostridioides Difficile Infection
Ivonescimab InjectionPhase 3Non-Small Cell Lung Cancer
Price & technical context
3-month
+10.7%
6-month
-16.1%
12-month
-24.9%
52-wk range
$12.43–$26.38
vs 50-day MA
-13.8%
vs 200-day MA
-12.4%
Realized vol
76.6%
Max drawdown
-66.1%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for SMMT (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.